S863 Impact of Duration of GLP-1 Receptor Agonist Therapy in Endoscopic Outcomes

Beatriz Torre,Akash Patel,Benjamin Young,Michael J. DiMarino,Katherine Duffey,Nicholas Noverati,Charles Kistler
DOI: https://doi.org/10.14309/01.ajg.0001032820.41709.eb
2024-10-26
The American Journal of Gastroenterology
Abstract:Glucagon-Like Peptide-1 (GLP-1) is a type of incretin hormone that has been shown to delay gastric emptying, increase satiety and improve glucose regulation. GLP-1 receptor agonists (GLP-1RA) have become increasingly common for the treatment of type 2 diabetes and obesity. Despite this increase in use, there remains a paucity of data evaluating their effects on endoscopic procedures. In this study, we evaluated the effects of different GLP-1RAs, dosing, and length of therapy and its impact on endoscopic outcomes.
gastroenterology & hepatology
What problem does this paper attempt to address?